Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport in pediatric lower limb spasticity
NCT01249417Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jul 2011
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of abobotulinumtoxinA in Spasticity, sponsored by Ipsen. Started Jul 2011; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT01249417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01249417.